Myasthenia Gravis and Its Comorbidities | 46339

Journal of Neurology & Neurophysiology

ISSN - 2155-9562


Myasthenia Gravis and Its Comorbidities

Bernardo Cacho Diaz, Paola Flores-Gavilan, Guillermo Garcia-Ramos and Nydia A. Lorenzana-Mendoza

Background: Myasthenia gravis (MG) is an unpredicted neurologic disorder that may cause death; previous reports have failed to find a prognostic marker for the disease. Aim: To determine the impact of comorbidities in patients with Myasthenia gravis. Material and Methods: From January of 2002 to February of 2008 a database was created for patients with Myasthenia gravis (MG). The following variables were studied: age at onset of MG, gender, diabetes mellitus, dyslipidemia, arterial hypertension, dysthyroidism, autoimmune disease, thymectomy procedure and histopathologic result, myasthenic crisis, emergency room visits due to weakness, use and maximum dose of pyridostigmine, prednisone and azathioprine. Results: In a total of 253 patients, we found comorbidities in 73%. The most frequent associated disorders were dyslipidemia, thyroid disease, diabetes, hypertension and other autoimmune conditions. Patients with MG and thymoma, diabetes, dyslipidemia, dysthyroidism and/or hypertension had higher rates of ER visits, myasthenic crises, and required higher doses of drugs. Conclusions: This study demonstrates that comorbidities are frequent in patients with MG (73%) and that they might worsen the prognosis of MG.